Back to top
more

Exelixis (EXEL)

(Delayed Data from NSDQ)

$22.40 USD

22.40
1,189,759

-0.15 (-0.67%)

Updated Jul 12, 2024 04:00 PM ET

After-Market: $22.41 +0.01 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Calithera's Kidney Cancer Candidate Gets Fast Track Status

Calithera Biosciences' (CALA) lead pipeline candidate, CB-839, gets fast track status in the United States for the treatment of kidney cancer.

    Exelixis (EXEL) in Focus: Stock Moves 7.7% Higher

    Exelixis (EXEL) was a big mover last session, as the company saw its shares rise nearly 8% on the day.

      Moving Average Crossover Alert: Exelixis, Inc. (EXEL)

      Moving Average Crossover Alert: Exelixis, Inc. (EXEL)

        Weakness Seen in Exelixis (EXEL) Estimates: Should You Stay Away?

        Exelixis (EXEL) has witnessed a significant price decline in the past four weeks, and has seen negative earnings estimate revisions for the current quarter and year.

          Why Is Exelixis (EXEL) Down 17.2% Since Its Last Earnings Report?

          Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

            Exelixis Cabometyx Gets Positive CHMP Opinion in Europe

            Exelixis' European partner, Ipsen, obtains positive opinion from the CHMP for the use of Cabometyx in the first-line treatment of advanced renal cell carcinoma.

              Exelixis (EXEL) Q4 Earnings Meet Estimates, Revenues Beat (revised)

              Exelixis' (EXEL) fourth-quarter results were positive wherein sales beat estimates on the back of Cabometyx growth while earnings met estimates.

                Perrigo (PRGO) Postpones Q4 Earnings Results, Shares Down

                Perrigo (PRGO) to reschedule fourth-quarter 2017 and full-year earnings results. However, the company releases preliminary unaudited numbers for the full year.

                  Exelixis (EXEL) Q4 Earnings Meet Estimates, Revenues Beat

                  Exelixis' (EXEL) fourth-quarter results were positive wherein sales beat estimates on the back of Cabometyx growth while earnings met estimates.

                    Endocyte (ECYT) Reports Wider-Than-Estimated Loss in Q4

                    Endocyte, Inc. (ECYT) posts wider-than-expected loss in the fourth quarter of 2017. The company finalized a phase III VISION trial design for 177Lu-PSMA-617 following a successful End of Phase II meeting with the FDA.

                      Emergent (EBS) Q4 Earnings Beat Estimates, 2018 View Solid

                      Emergent's (EBS) earnings and revenues beat estimates in Q4. The top line also improves year over year on higher product sales.

                        Achillion (ACHN) Q4 Loss Widens, Plans Job Cuts to Save Cost

                        Achillion Pharmaceuticals' (ACHN) fourth-quarter loss wider than estimates. The company is focusing on operational restructuring to save costs.

                          Corcept's (CORT) Earnings and Sales Meet Estimates in Q4

                          Corcept (CORT) reports in-line results for the fourth quarter of 2017 and also announces top-line interim phase II data for its pipeline candidate relacorilant.

                            Medicines Company (MDCO) Reports Q4 Loss, Revenues Slump Y/Y

                            Medicines Company (MDCO) incurs wider-than-expected loss in the fourth quarter of 2017. Moreover, the top line declines year over year on low Angiomax sales.

                              Will Mylan (MYL) Disappoint Investors This Earnings Season?

                              During the Q4 earnings call, investors are expected to remain focused on the performance of Mylan's (MYL) EpiPen, newly launched drugs and the progress of the biosimilars pipeline.

                                Will Cabometyx Fuel Exelixis' (EXEL) Earnings in Q4 Again?

                                Exelixis (EXEL) is likely to beat on earnings in the fourth quarter (results due on Feb 26) driven by growth in Cabometyx sales.

                                  What's in Store for Agenus (AGEN) This Earnings Season?

                                  Agenus (AGEN) is expected to provide updates on pipeline candidates when it reports Q4 numbers on Mar 8.

                                    Key Factors to Influence Penumbra's (PEN) Earnings in Q4

                                    Penumbra (PEN) expects to gain from solid performance by neuro and peripheral vascular arms in Q4. Strong growth across all geographies is likely to drive the top line.

                                      What's in Store for Veeva Systems (VEEV) in Q4 Earnings?

                                      Consistent focus on Subscription Services is likely to drive Veeva Systems (VEEV) in Q4.

                                        Is a Beat in Store for Inogen (INGN) This Earnings Season?

                                        Strong product portfolio and a unique direct-to-consumer business model are expected to drive Inogen (INGN) in Q4.

                                          Will ACADIA (ACAD) Disappoint Investors in Q4 Earnings?

                                          ACADIA (ACAD) is expected to provide further update on the progress of Nuplazid when it reports Q4 results on Feb 27.

                                            What's in Store for Juno Therapeutics (JUNO) in Q4 Earnings?

                                            Although Juno Therapeutics' (JUNO) product portfolio lacks revenue figures, the company's most advanced pipeline candidates, JCAR017 and JCAR014, might still drive the stock in Q4.

                                              Can PBM Unit Drive Express Scripts' (ESRX) Earnings in Q4?

                                              Express Scripts (ESRX) expects Q4 results to show earnings growth on strength in PBM segment.

                                                What to Expect From BioMarin (BMRN) This Earnings Season?

                                                BioMarin (BMRN) is likely to see continued momentum in Kuvan sales in Q4. On the call, management is likely to comment on Brineura's launch progress and on the launch preparation for pegvaliase.

                                                  What's in the Cards for Geron (GERN) This Earnings Season?

                                                  With no approved product in Geron's (GERN) portfolio, investor focus is likely to remain on its sole pipeline candidate, imetelstat, in the Q4 release.